Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

3.10
BATS BZX Real-Time Price
As of 12:53pm ET
 -0.01 / -0.32%
Today’s Change
2.02
Today|||52-Week Range
6.56
-49.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$97.6M

Company Description

Ohr Pharmaceutical, Inc. is a pharmaceutical company, which focuses on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. The company products include Squalamine eye drops for the treatment of the wet form of age-related macular degeneration (wet AMD) with a potential for expansion into other indications such as diabetic macular edema (DME) and retinal vein occlusions (RVO) and OHR/AVR 118 for the treatment of Cancer Cachexia. Ohr Pharmaceutical was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.

Contact Information

Ohr Pharmaceutical, Inc.
800 3rd Avenue
New York New York 10022
P:(212) 682-8452
Investor Relations:

Employees

Shareholders

Mutual fund holders3.95%
Individual stakeholders21.33%
Other institutional16.76%

Top Executives

Jason Scott SlakterChief Executive Officer & Director
Samuel I. BackenrothCFO, CAO & VP-Business Development
Glenn L. StollerChief Scientific Officer
Avner IngermanChief Clinical Officer
Marlene ModiVP-Preclinical Development & Regulatory Affairs